{"id":"carbamazepine-tegretol","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Dizziness"},{"rate":"15-30","effect":"Ataxia"},{"rate":"25-35","effect":"Diplopia"},{"rate":"10-25","effect":"Nausea"},{"rate":"1-8","effect":"Rash (including Stevens-Johnson syndrome)"},{"rate":"5-15","effect":"Hyponatremia"},{"rate":"0.1-0.5","effect":"Agranulocytosis"},{"rate":"1-3","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL108","moleculeType":"Small molecule","molecularWeight":"236.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug binds to inactivated sodium channels in the brain, preventing their reopening and thereby reducing the frequency of action potentials. This membrane-stabilizing effect suppresses abnormal electrical activity in the central nervous system, making it effective for controlling seizures and neuropathic pain. It also has mild anticholinergic and antidiuretic properties.","oneSentence":"Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:08.022Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (generalized tonic-clonic and partial seizures)"},{"name":"Trigeminal neuralgia"},{"name":"Bipolar disorder (acute mania and maintenance)"},{"name":"Neuropathic pain"}]},"trialDetails":[{"nctId":"NCT07198035","phase":"PHASE1","title":"A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-09-18","conditions":"Healthy Adults","enrollment":12},{"nctId":"NCT04923659","phase":"EARLY_PHASE1","title":"Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-05-25","conditions":"Low Intensity Focussed Ultrasound","enrollment":20},{"nctId":"NCT06633419","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-18","conditions":"Healthy","enrollment":14},{"nctId":"NCT05552196","phase":"PHASE1","title":"A Study of Ponesimod in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2022-10-18","conditions":"Healthy","enrollment":28},{"nctId":"NCT06751017","phase":"PHASE1","title":"A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2024-12-17","conditions":"COVID-19","enrollment":16},{"nctId":"NCT06849219","phase":"PHASE4","title":"Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2024-09-21","conditions":"Trigeminal Neuralgia","enrollment":122},{"nctId":"NCT05965219","phase":"PHASE1","title":"A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Cerevel Therapeutics, LLC","startDate":"2023-08-15","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT06005688","phase":"PHASE1","title":"A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-08-18","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT05748236","phase":"PHASE4","title":"The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy","status":"UNKNOWN","sponsor":"Dhaka Medical College","startDate":"2022-11-01","conditions":"Focal Epilepsy","enrollment":70},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT02623504","phase":"PHASE4","title":"DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder","status":"TERMINATED","sponsor":"Validus Pharmaceuticals","startDate":"2016-10-24","conditions":"Bipolar Disorder","enrollment":17},{"nctId":"NCT05697614","phase":"PHASE4","title":"The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children","status":"UNKNOWN","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2023-03-01","conditions":"Drug Resistant Epilepsy","enrollment":100},{"nctId":"NCT05635071","phase":"PHASE2, PHASE3","title":"Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-12-01","conditions":"Uterine Adhesions","enrollment":90},{"nctId":"NCT00621751","phase":"NA","title":"Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-02","conditions":"Traumatic Brain Injury","enrollment":70},{"nctId":"NCT01379469","phase":"PHASE2","title":"Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-01","conditions":"Alpha-1-antitrypsin Deficiency, Liver Cirrhosis","enrollment":20},{"nctId":"NCT01243177","phase":"PHASE3","title":"Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2011-04","conditions":"Epilepsy, Monotherapy","enrollment":888},{"nctId":"NCT02870283","phase":"PHASE4","title":"Cost- Effectiveness and Quality of Life Assessment in Mood Disorder","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","startDate":"2010-05","conditions":"Bipolar Disorder","enrollment":107},{"nctId":"NCT02912364","phase":"PHASE4","title":"Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults","status":"COMPLETED","sponsor":"Stanford University","startDate":"2016-07","conditions":"Epilepsy","enrollment":46},{"nctId":"NCT00612235","phase":"","title":"Premenstrual Dysphoric Disorder and Antiepileptic Drugs","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-04","conditions":"Epilepsy","enrollment":80},{"nctId":"NCT01465997","phase":"PHASE3","title":"Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-05","conditions":"Epilepsy, Monotherapy","enrollment":551},{"nctId":"NCT02705768","phase":"PHASE4","title":"Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2016-04","conditions":"Seizures, Focal","enrollment":90},{"nctId":"NCT01954121","phase":"PHASE3","title":"Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2013-09","conditions":"Epilepsy, Partial Seizures","enrollment":436},{"nctId":"NCT00224952","phase":"","title":"Pathogenesis of Adverse Drug Reactions","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2002-07","conditions":"Seizures","enrollment":274},{"nctId":"NCT01089855","phase":"PHASE4","title":"Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-12","conditions":"Neuropathic Pain","enrollment":123},{"nctId":"NCT02214615","phase":"PHASE4","title":"Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations","status":"COMPLETED","sponsor":"VA Connecticut Healthcare System","startDate":"2014-04","conditions":"Erythromelalgia","enrollment":2},{"nctId":"NCT02429596","phase":"PHASE4","title":"A Trial of Generic Substitution of Antiepileptic Drugs","status":"UNKNOWN","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2012-05","conditions":"Epilepsy","enrollment":200},{"nctId":"NCT02208492","phase":"PHASE4","title":"The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-09","conditions":"Focal Epilepsy","enrollment":75},{"nctId":"NCT02132897","phase":"PHASE1","title":"Fed Bioequivalence Study of CBZ Formulations","status":"COMPLETED","sponsor":"Center for Clinical Pharmacology Research Bdbeq S.A.","startDate":"2014-05","conditions":"Bio-equivalence Study, Fed Conditions","enrollment":20},{"nctId":"NCT00350857","phase":"PHASE4","title":"The Young Adult and Pediatric Bipolar Study","status":"COMPLETED","sponsor":"Validus Pharmaceuticals","startDate":"2006-07","conditions":"Bipolar I Disorder","enrollment":161},{"nctId":"NCT01530022","phase":"PHASE1","title":"Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-05","conditions":"Healthy","enrollment":60},{"nctId":"NCT00610571","phase":"PHASE1","title":"Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas","status":"COMPLETED","sponsor":"Katy Peters","startDate":"2004-04","conditions":"Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma","enrollment":62},{"nctId":"NCT00612638","phase":"PHASE1","title":"Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas","status":"COMPLETED","sponsor":"Duke University","startDate":"2005-01","conditions":"Glioblastoma, Gliosarcoma","enrollment":96},{"nctId":"NCT00734864","phase":"PHASE1","title":"Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma","status":"WITHDRAWN","sponsor":"Annick Desjardins","startDate":"2009-06","conditions":"Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma","enrollment":""},{"nctId":"NCT01390909","phase":"","title":"Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Epilepsy","enrollment":12386},{"nctId":"NCT00894010","phase":"PHASE2","title":"Photosensitivity Proof of Concept Trial","status":"COMPLETED","sponsor":"The Epilepsy Study Consortium","startDate":"2009-05","conditions":"Photosensitive Epilepsy","enrollment":6},{"nctId":"NCT00913107","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2007-09","conditions":"Trigeminal Neuralgia","enrollment":21},{"nctId":"NCT00181870","phase":"PHASE4","title":"Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-07","conditions":"Bipolar Disorder, Mania","enrollment":33},{"nctId":"NCT00896987","phase":"PHASE4","title":"Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies","status":"COMPLETED","sponsor":"Korean Epilepsy Society","startDate":"2006-05","conditions":"Epilepsy","enrollment":121},{"nctId":"NCT00203567","phase":"PHASE4","title":"Carbamazepine Extended-Release for the Treatment of Bipolar Depression","status":"COMPLETED","sponsor":"Tuscaloosa Research & Education Advancement Corporation","startDate":"2005-08","conditions":"Bipolar Depression","enrollment":25},{"nctId":"NCT00542802","phase":"PHASE3","title":"Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis","status":"UNKNOWN","sponsor":"Scienze Neurologiche Ospedaliere","startDate":"2007-09","conditions":"Epileptic Seizures, Stroke","enrollment":630},{"nctId":"NCT00006395","phase":"PHASE4","title":"Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2000-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT00325286","phase":"PHASE4","title":"Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder","status":"UNKNOWN","sponsor":"Creighton University","startDate":"2006-05","conditions":"Bipolar Disorder","enrollment":20},{"nctId":"NCT00000441","phase":"PHASE4","title":"Drug Therapy for Alcohol Detoxification","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"","conditions":"Alcoholism","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ASTHENIA"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"CONVULSION"},{"count":1,"reaction":"DELUSION"},{"count":1,"reaction":"DEPRESSED MOOD"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DRUG DOSE OMISSION"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"NAUSEA"},{"count":1,"reaction":"RENAL PAIN"}],"_approvalHistory":[],"publicationCount":129,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tegretol","Carbamazepine (Tegretol-XR) placebo."],"phase":"marketed","status":"active","brandName":"Carbamazepine (Tegretol)","genericName":"Carbamazepine (Tegretol)","companyName":"Korean Epilepsy Society","companyId":"korean-epilepsy-society","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels. Used for Epilepsy (generalized tonic-clonic and partial seizures), Trigeminal neuralgia, Bipolar disorder (acute mania and maintenance).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}